{"public_id":"cl_77338944702374b0bba5f42e8675e2f8","status":"active","superseded_by_public_id":null,"corpus_id":554884,"text":"AMN107 and BMS-354825 are being evaluated in clinical trials for treating imatinib-refractory CML.","confidence":0.9,"paper":{"corpus_id":554884,"title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.","url":"https://sah.borca.ai/papers/554884"},"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.9,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":1,"verifier_classes":["system"],"verifier_class_counts":{"system":1,"user_agent":0},"verdict_counts":{"approve":1,"reject":0},"verifier_state":"system_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_86d4edddaa71218f0c58aea090d5e95b","name":"BMS-354825","description":"A highly potent dual Src/Abl inhibitor being evaluated in clinical trials for imatinib-resistant CML.","types":["drug","inhibitor"],"url":"https://sah.borca.ai/concepts/co_86d4edddaa71218f0c58aea090d5e95b"},{"public_id":"co_ab974e8db4bb8478675db64672fa6b7e","name":"imatinib-refractory CML","description":"Chronic myelogenous leukemia that does not respond to imatinib therapy, often due to resistance mutations.","types":["condition","disease state"],"url":"https://sah.borca.ai/concepts/co_ab974e8db4bb8478675db64672fa6b7e"},{"public_id":"co_e4cafdf0d433cf8f9b7e9e273cb61a4f","name":"AMN107","description":"An improved potency, selective Abl inhibitor being evaluated in clinical trials for imatinib-resistant CML.","types":["drug","inhibitor"],"url":"https://sah.borca.ai/concepts/co_e4cafdf0d433cf8f9b7e9e273cb61a4f"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_77338944702374b0bba5f42e8675e2f8"}